Contract Management: Observations on DOD's Financial Relationship With the Anthrax Vaccine Manufacturer
T-NSIAD-99-214
Published: Jun 30, 1999. Publicly Released: Jun 30, 1999.
Skip to Highlights
Highlights
Pursuant to a congressional request, GAO discussed the contractual relationship between the Department of Defense (DOD) and the BioPort Corporation for production of the anthrax vaccine, focusing on: (1) DOD's investment in BioPort's biologic facility and contracts to produce the vaccine; (2) BioPort's cash flow situation; and (3) proposals to improve the company's financial health.
Full Report
Office of Public Affairs
Topics
Biological warfareChemical agentsBiological agentsAnthraxChemical warfareContract administrationDefense procurementDepartment of Defense contractorsFinancial analysisImmunization services